

<b>Informazione Regolamentata n. 20106-48-2023</b>	<b>Data/Ora Inizio Diffusione 10 Novembre 2023 12:05:43</b>	<b>Euronext Star Milan</b>
--	---	----------------------------

Societa' : PHARMANUTRA

Identificativo : 183174

Informazione  
Regolamentata

Nome utilizzatore : PHARMANUTRAN04 - Roberto Lacorte

Tipologia : REGEM

Data/Ora Ricezione : 10 Novembre 2023 12:05:42

Data/Ora Inizio  
Diffusione : 10 Novembre 2023 12:05:43

Oggetto : INTERIM MANAGMENT REPORT AS OF  
30 SEPTEMBER 2023

*Testo del comunicato*

Vedi allegato.

## PHARMANUTRA S.P.A.: INTERIM MANAGEMENT REPORT AS OF 30 SEPTEMBER 2023

Pisa, November 10<sup>th</sup> 2023 - PharmaNutra S.p.A. (MTA; Ticker PHN) announces that the Interim Management Report as of 30 September 2023, as approved by the Board of Directors of the Company on November 6<sup>th</sup> 2023, is available at the Company's registered office, on PharmaNutra S.p.A. website ([www.pharmanutra.it](http://www.pharmanutra.it), section *Investor Relations*) and on the authorized storage mechanism "eMarket Storage" available on the website ([www.emarketstorage.it](http://www.emarketstorage.it)).

### PharmaNutra S.p.A.

Founded and led by Chairman Andrea Lacorte and Vice Chairman Roberto Lacorte, PharmaNutra is a company established in 2003 that develops unique nutritional supplements and innovative medical devices, taking care of the entire production process, from proprietary raw materials to the finished product. PharmaNutra is a leader in the production of iron-based nutritional supplements under the SiderAL® brand, where it holds important patents on Sucrosomial® Technology, and is considered one of the emerging top players in the medical device sector dedicated to restoring joint capacity thanks to the Cetilar® brand. The effectiveness of the products is demonstrated by a number of scientific evidences, including more than 120 publications. In Italy, the sales activity is carried out through a network of over 160 Commercial Scientific Agents serving the medical class and dedicated to the exclusive marketing of products to pharmacies and parapharmacies throughout the national territory. Sales abroad are guaranteed in over 71 countries through 45 partners selected among the leading pharmaceutical companies. Over the years, the Group has developed a precise strategy in the management and production of intellectual property, based on the integrated management of all components: proprietary raw materials, patents, trademarks and clinical evidence.

[PharmaNutra.it](http://PharmaNutra.it)

For further details:

### PharmaNutra S.p.A.

Via Campodavella 1 - 56122 Pisa, Italy  
Tel. +39 050 7846500  
[investorrelation@PharmaNutra.it](mailto:investorrelation@PharmaNutra.it)

Internal Press Office  
[press@calabughi.com](mailto:press@calabughi.com)

### Press Office - Spriano Communication & Partners

Via Santa Radegonda, 16 - 20121 Milan, Italy  
Tel. +39 02 83635708

Matteo Russo  
[mrusso@sprianocommunication.com](mailto:mrusso@sprianocommunication.com)  
Cristina Tronconi  
[ctronconi@sprianocommunication.com](mailto:ctronconi@sprianocommunication.com)

Fine Comunicato n.20106-48

Numero di Pagine: 3